Comparative Effectiveness and Safety of Fluticasone-Umeclidinium-Vilanterol and Beclomethasone-Glycopyrronium-Formoterol Single-Inhaler Triple Therapies for COPD: Real-World Observational Study - PubM
3 days ago
- #triple therapy
- #COPD
- #observational study
- Real-world study compares fluticasone-umeclidinium-vilanterol (FUV, once daily) and beclomethasone-glycopyrronium-formoterol (BEGF, twice daily) single-inhaler triple therapies for COPD.
- FUV was associated with a lower incidence of moderate or severe exacerbations compared to BEGF (hazard ratio 0.91 for first moderate/severe exacerbation).
- FUV showed a higher incidence of severe pneumonia requiring hospitalization in subgroups, particularly GOLD Group E patients and those with blood eosinophil count ≤300 cells/µL.